Results
Pappas Capital LLC
07/26/2026 | Press release | Distributed by Public on 07/26/2026 20:25
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for th...
News | 07. 26. 2026
Minoryx
BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd) negative brain lesions. European Commission approval is expected by the end of September 2026.
Pappas Capital LLC published this content on July 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 27, 2026 at 02:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]